Sangamo Announces ASGCT 2024

Executive Leadership Team

Bettina Cockroft, M.D.

Chief Medical Officer

Bettina Cockroft, M.D., M.B.A., has served as Senior Vice President and Chief Medical Officer since September 2019 and oversees all clinical development activities and operations. She has over 20 years of experience in the biopharmaceutical industry and has worked across multiple therapeutic areas and led programs in several countries. Prior to joining Sangamo, Dr. Cockroft served on the senior leadership team at Cytokinetics, Inc., where she was responsible for clinical development of fast skeletal muscle troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy. Before that, Dr. Cockroft served as Chief Medical Officer of Auris Medical AG, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career.

Dr. Cockroft earned her M.B.A. at MIT Sloan School of Management and her M.D. from the University of Genova.